Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555614 | 1.00 | PLCG1 (0.33) | PLCG1POLBSMN1; SMN2HTTHTR2A | |
| SCHEMBL3555617 | 1.00 | PLCG1 (0.33) | PLCG1POLBSMN1; SMN2HTTHTR2A | |
| SCHEMBL2929065 | 0.93 | PLCG1 (0.32) | PLCG1SMN1; SMN2HTTHTR2AALDH1A1 | |
| SCHEMBL2925751 | 0.91 | ATM (0.34) | PLCG1HTTHTR2AATMALDH1A1 | |
| SCHEMBL3554113 | 0.91 | ATM (0.34) | PLCG1HTTHTR2AATMALDH1A1 | |
| SCHEMBL3554106 | 0.91 | ATM (0.34) | PLCG1HTTHTR2AATMALDH1A1 | |
| SCHEMBL3549897 | 0.90 | TDP1 (0.35) | PLCG1SMN1; SMN2ATMALDH1A1 | |
| SCHEMBL3044789 | 0.90 | TDP1 (0.35) | PLCG1SMN1; SMN2ATMALDH1A1 | |
| SCHEMBL3549899 | 0.90 | TDP1 (0.35) | PLCG1SMN1; SMN2ATMALDH1A1 | |
| SCHEMBL2922953 | 0.90 | PLCG1 (0.33) | PLCG1HTTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499620-B1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | WYETH CORP (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-1988093-A1 | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | Wyeth a Corporation of the State of Delaware (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | PLCG1 3678/4885POLB 338/4885SMN1; SMN2 1450/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | PLCG1 2492/4885POLB 453/4885SMN1; SMN2 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.